Background.-Intrapartum antibiotics can prevent early-onset neonatal group B streptococcal (GBS) disease but have not been widely used.
Obstacles include difficulty in implementing screening for GBS colonization and uncertainty about cost-effectiveness.
The GBS vaccines for disease prevention are now being developed.
Methods.-We developed a decision analysis model and used standard costeffectiveness and cost-benefit analysis methods.
We compared the outcomes and costs of the recent practice of no intervention with those expected for three prevention strategies: (1) intrapartum antibiotics administered to colonized women with labor complications, (2) an alternative strategy that does not require screening but uses epidemiologic criteria and labor complications to target intrapartum antibiotics, and (3) maternal vaccination.
Mots-clés Pascal : Infection, Bactériose, Economie santé, Prévention, Nouveau né, Homme, Chimiothérapie, Antibiotique, Streptococcus B, Streptococcaceae, Micrococcales, Bactérie, Streptococcie
Mots-clés Pascal anglais : Infection, Bacteriosis, Health economy, Prevention, Newborn, Human, Chemotherapy, Antibiotic, Streptococcus B, Streptococcaceae, Micrococcales, Bacteria, Streptococcal infection
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 94-0004499
Code Inist : 002B02S02. Création : 199406.